ATE146971T1 - Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu - Google Patents

Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu

Info

Publication number: ATE146971T1
Authority: AT; Austria
Prior art keywords: tnf; antibody; xanthine; range; xanthine derivative
Prior art date: 1990-11-01

Application number

AT91918565T

Other languages

English (en)

Inventor

Hiristo Anagnostopulos

Ulrich Gebert

Heinz Hanel

Michael Limbert

Mark William Bodmer

Gerald Anthony Higgs

Original Assignee

Celltech Therapeutics Ltd

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-01

Filing date

1991-10-30

Publication date

1997-01-15

1991-10-30 Application filed by Celltech Therapeutics Ltd, Hoechst Ag filed Critical Celltech Therapeutics Ltd

1997-01-15 Application granted granted Critical

1997-01-15 Publication of ATE146971T1 publication Critical patent/ATE146971T1/de

Links

LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 6
239000012634 fragment Substances 0.000 title abstract 4
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
238000002648 combination therapy Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 abstract 3
206010040070 Septic Shock Diseases 0.000 abstract 3
206010014824 Endotoxic shock Diseases 0.000 abstract 1
NWXULHNEYYFVMF-UHFFFAOYSA-N albifylline Chemical compound O=C1N(CCCCC(C)(C)O)C(=O)N(C)C2=C1NC=N2 NWXULHNEYYFVMF-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000004957 immunoregulator effect Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
229960001476 pentoxifylline Drugs 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000036303 septic shock Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT91918565T 1990-11-01 1991-10-30 Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu ATE146971T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909023783A GB9023783D0 (en)	1990-11-01	1990-11-01	Pharmaceutical product

Publications (1)

Publication Number	Publication Date
ATE146971T1 true ATE146971T1 (de)	1997-01-15

Family

ID=10684716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91918565T ATE146971T1 (de)	1990-11-01	1991-10-30	Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu

Country Status (15)

Country	Link
EP (1)	EP0564461B1 (de)
JP (1)	JP3468515B2 (de)
KR (1)	KR930701970A (de)
AT (1)	ATE146971T1 (de)
AU (1)	AU653180B2 (de)
CA (1)	CA2094154A1 (de)
DE (1)	DE69123984T2 (de)
DK (1)	DK0564461T3 (de)
ES (1)	ES2096662T3 (de)
GB (1)	GB9023783D0 (de)
GR (1)	GR3022210T3 (de)
HU (1)	HUT70267A (de)
NO (1)	NO931580D0 (de)
WO (1)	WO1992007585A1 (de)
ZA (1)	ZA918712B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9109645D0 (en) *	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2146647C (en) *	1992-10-08	2009-05-05	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
US6770279B1 (en)	1992-10-08	2004-08-03	The Kennedy Institute Of Rheumatology	TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
AU1090795A (en)	1993-11-12	1995-05-29	Cell Therapeutics, Inc.	Method for preventing tissue injury from hypoxia
DE4411660A1 (de) *	1994-04-05	1995-10-12	Hoechst Ag	Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
WO1998024463A2 (en) *	1996-12-06	1998-06-11	Amgen Inc.	Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP1352656A3 (de) *	1996-12-06	2004-02-04	Amgen Inc.	Kombinationtherapie mit einem tnf-bindendem Protein zür behandlung von durch tnf verursachten Erkrangungen
US6294350B1 (en) *	1997-06-05	2001-09-25	Dalhousie University	Methods for treating fibroproliferative diseases
US6395273B1 (en) *	1998-06-10	2002-05-28	Promega Corporation	Prevention and treatment of inflammatory bowel disease

1990
- 1990-11-01 GB GB909023783A patent/GB9023783D0/en active Pending
1991
- 1991-10-30 KR KR1019930701250A patent/KR930701970A/ko not_active Withdrawn
- 1991-10-30 DK DK91918565.2T patent/DK0564461T3/da active
- 1991-10-30 AU AU87583/91A patent/AU653180B2/en not_active Ceased
- 1991-10-30 HU HU9301093A patent/HUT70267A/hu unknown
- 1991-10-30 EP EP91918565A patent/EP0564461B1/de not_active Expired - Lifetime
- 1991-10-30 CA CA002094154A patent/CA2094154A1/en not_active Abandoned
- 1991-10-30 JP JP51773591A patent/JP3468515B2/ja not_active Expired - Lifetime
- 1991-10-30 ES ES91918565T patent/ES2096662T3/es not_active Expired - Lifetime
- 1991-10-30 AT AT91918565T patent/ATE146971T1/de not_active IP Right Cessation
- 1991-10-30 WO PCT/GB1991/001907 patent/WO1992007585A1/en not_active Ceased
- 1991-10-30 DE DE69123984T patent/DE69123984T2/de not_active Expired - Fee Related
- 1991-11-01 ZA ZA918712A patent/ZA918712B/xx unknown
1993
- 1993-04-30 NO NO931580A patent/NO931580D0/no unknown
1997
- 1997-01-03 GR GR960403495T patent/GR3022210T3/el unknown

Also Published As

Publication number	Publication date
DE69123984T2 (de)	1997-05-22
HU9301093D0 (en)	1993-07-28
ZA918712B (en)	1992-09-30
DE69123984D1 (de)	1997-02-13
GB9023783D0 (en)	1990-12-12
HUT70267A (en)	1995-09-28
ES2096662T3 (es)	1997-03-16
EP0564461A1 (de)	1993-10-13
EP0564461B1 (de)	1997-01-02
AU8758391A (en)	1992-05-26
CA2094154A1 (en)	1992-05-02
AU653180B2 (en)	1994-09-22
JPH06502629A (ja)	1994-03-24
GR3022210T3 (en)	1997-04-30
NO931580D0 (no)	1993-04-30
WO1992007585A1 (en)	1992-05-14
JP3468515B2 (ja)	2003-11-17
KR930701970A (ko)	1993-09-08
DK0564461T3 (da)	1997-01-20

Similar Documents

Publication	Publication Date	Title
DE69724451D1 (de)	2003-10-02	Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
DE69123984D1 (de)	1997-02-13	Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu
BRPI0407058A (pt)	2006-01-17	Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
HUT76875A (en)	1997-12-29	Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
BG110703A (en)	2010-10-29	PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
NZ324500A (en)	1999-08-30	Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DE68927671D1 (de)	1997-02-27	Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
IL103981A0 (en)	1993-05-13	Pharmaceutical compositions for treatment of multiple sclerosis
NO985150D0 (no)	1998-11-04	Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft
RU95113862A (ru)	1997-06-10	Производные пирролопиримидинов, фармацевтическая композиция, промежуточные соединения
NO922457L (no)	1992-06-19	Antistoffantagonister av humant interleukin-4
NO307645B1 (no)	2000-05-08	Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
WO1992012715A3 (en)	1992-09-03	The use of loperamide and related compounds for treatment of respiratory disease symptoms
ATE120372T1 (de)	1995-04-15	Antikörper für die antilymphozyten- antikörpertherapie.
WO1996020950A3 (en)	1996-09-12	Compositions and methods for treating rheumatoid arthritis
WO2024249839A8 (en)	2025-10-09	Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure
WO2003097082A3 (en)	2004-12-09	Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2023166318A3 (en)	2023-10-12	Therapeutic antibodies
WO2002009751A8 (en)	2003-04-24	COMPOSITIONS FOR INDUCING SELF-SPECIFIC ANTI-IgE ANTIBODIES AND USES THEREOF
WO2001072334A3 (en)	2002-02-21	Methods for treating disease with antibodies to cxcr3
Roszkiewicz et al.	2018	Tocilizumab w leczeniu młodzieńczego idiopatycznego zapalenia stawów o początku uogólnionym–doświadczenia własne
NO972906D0 (no)	1997-06-20	4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
WO1996020690A3 (en)	1996-09-06	3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds
GB2233559A (en)	1991-01-16	Antibodies for use in antilymphocyte antibody therapy

Legal Events

Date	Code	Title	Description
1997-05-15	UEP	Publication of translation of european patent specification
1999-01-15	REN	Ceased due to non-payment of the annual fee